Bjørn Østenstad

3.5k total citations
60 papers, 2.6k citations indexed

About

Bjørn Østenstad is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Bjørn Østenstad has authored 60 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 28 papers in Pathology and Forensic Medicine and 22 papers in Immunology. Recurrent topics in Bjørn Østenstad's work include Lymphoma Diagnosis and Treatment (28 papers), Immune Cell Function and Interaction (14 papers) and CAR-T cell therapy research (11 papers). Bjørn Østenstad is often cited by papers focused on Lymphoma Diagnosis and Treatment (28 papers), Immune Cell Function and Interaction (14 papers) and CAR-T cell therapy research (11 papers). Bjørn Østenstad collaborates with scholars based in Norway, Sweden and Denmark. Bjørn Østenstad's co-authors include Harald Holte, J Sjöström, Carl Blomqvist, Ingvil Mjaaland, Nils‐Olof Bengtsson, Hans Hagberg, Christer Sundström, Martin Erlanson, Terje Risberg and Peter de Nully Brown and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Bjørn Østenstad

60 papers receiving 2.5k citations

Peers

Countries citing papers authored by Bjørn Østenstad

Since Specialization

Citations

This map shows the geographic impact of Bjørn Østenstad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bjørn Østenstad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bjørn Østenstad more than expected).

Fields of papers citing papers by Bjørn Østenstad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bjørn Østenstad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bjørn Østenstad. The network helps show where Bjørn Østenstad may publish in the future.

Co-authorship network of co-authors of Bjørn Østenstad

This figure shows the co-authorship network connecting the top 25 collaborators of Bjørn Østenstad. A scholar is included among the top collaborators of Bjørn Østenstad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bjørn Østenstad. Bjørn Østenstad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma 2020 ·Blood ·(unknown), (unknown), Yngvild Nuvin Blaker, Chloé B. Steen, Ankush Sharma, Kushi Kushekhar, Saskia Meyer, Arne Kolstad, Klaus Beiske, Harald Holte, Bjørn Østenstad, Eva Kimby, Johanna Olweus, Kjetil Taskén, Suzanne Lorenz, Erlend B. Smeland, Ash A. Alizadeh, Kanutte Huse, June H. Myklebust	2
2	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma 2019 ·Cancer Immunology Research ·(unknown), Klaus Beiske, Yngvild Nuvin Blaker, (unknown), Harald Holte, Bjørn Østenstad, Eva Kimby, Hakan Köksal, Sébastien Wälchli, Baoyan Bai, Erlend B. Smeland, Ronald Levy, Arne Kolstad, Kanutte Huse, June H. Myklebust	82
3	No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy 2019 ·British Journal of Haematology ·(unknown), Harald Holte, Ingrid Glimelius, Magnus Björkholm, Gunilla Enblad, Martin Erlanson, Øystein Fluge, Helena Fohlin, Alexander Fosså, (unknown), Anita Gustavsson, (unknown), Johan Linderoth, Ole Nome, Marzia Palma, (unknown), Bjørn Østenstad, (unknown), Bengt Glimelius, Daniel Molin	18
4	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling 2017 ·Clinical Cancer Research ·(unknown), Kanutte Huse, Arne Kolstad, Klaus Beiske, Daniela Pende, Chloé B. Steen, Else Marit Inderberg, Ole Christian Lingjærde, Bjørn Østenstad, Erlend B. Smeland, Ronald Levy, Jonathan M. Irish, June H. Myklebust	76
5	Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by The Nordic Lymphoma Group 2014 ·Haematologica ·Elisa Jacobsen Pulczynski, Outi Kuittinen, Martin Erlanson, Hans Hagberg, Alexander Fosså, Mikael Eriksson, Marie Nordström, Bjørn Østenstad, Øystein Fluge, Sirpa Leppä, Bente Fiirgaard, (unknown), Unn‐Merete Fagerli	79
6	Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy 2013 ·Leukemia & lymphoma ·Björn E. Wahlin, Christer Sundström, Birgitta Sander, Birger Christensson, (unknown), (unknown), Harald Holte, Bjørn Østenstad, Peter de Nully Brown, Erlend B. Smeland, Eva Kimby	11
7	Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01 2012 ·Journal of Clinical Oncology ·Francesco d’Amore, Thomas Relander, Grete F. Lauritzsen, Esa Jantunen, Hans Hagberg, Harald Anderson, Harald Holte, Anders Österborg, Mats Merup, Peter de Nully Brown, Outi Kuittinen, Martin Erlanson, Bjørn Østenstad, (unknown), Ole Gadeberg, Christer Sundström, Jan Delabie, Elisabeth Ralfkiær, Martine Vornanen, Helle Toldbod	386
8	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study 2012 ·Annals of Oncology ·Harald Holte, Sirpa Leppä, Magnus Björkholm, Øystein Fluge, Sirkku Jyrkkiö, Jan Delabie, Christer Sundström, Marja‐Liisa Karjalainen‐Lindsberg, Martin Erlanson, Arne Kolstad, Alexander Fosså, Bjørn Østenstad, Eva Löfvenberg, Marie Nordström, Rita Janes, Lars Møller Pedersen, Henry A. Anderson, Mats Jerkeman, Mikael Eriksson	86
9	Upfront Autologuos Stem Cell Transplantation in Peripheral T-cell Lymphoma (NLG-T-01) 2012 ·Francesco d’Amore, Thomas Relander, Grete F. Lauritzsen, Esa Jantunen, H Hagberg, Henry A. Anderson, Harald Holte, Anders Österborg, Mats Merup, Peter de Nully Brown, Outi Kuittinen, Martin Erlanson, Bjørn Østenstad, (unknown), Ole Gadeberg, Christer Sundström, Jan Delabie, E. Ralfkiaer, Martine Vornanen, Helle Toldbod	1
10	T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab 2011 ·Clinical Cancer Research ·Björn E. Wahlin, Christer Sundström, Harald Holte, Hans Hagberg, Martin Erlanson, Herman Nilsson‐Ehle, Ola Lindén, Marie Nordström, Bjørn Østenstad, Christian H. Geisler, Peter de Nully Brown, Tuula Lehtinen, (unknown), Anne Tierens, Birgitta Sander, Birger Christensson, Eva Kimby	41
11	Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment 2011 ·Blood ·Olav Erich Yri, Dag Torfoss, Olav Hungnes, Anne Tierens, K. Waalen, Tone Nordøy, Susanne Dudman, Anette Kilander, Karin Fahl Wader, Bjørn Østenstad, Roald Ekanger, Peter Meyer, Arne Kolstad	119
12	Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor 2008 ·Thrombosis and Haemostasis ·Per Ole Iversen, Bjørn Østenstad, Nina Iversen, Pål André Holme, Per Morten Sandset, Helene F. S. Negaard	32
13	Increased acquired activated protein C resistance in unselected patients with hematological malignancies 2008 ·Journal of Thrombosis and Haemostasis ·Helene F. S. Negaard, Per Ole Iversen, Bjørn Østenstad, Marie‐Christine Mowinckel, Per Morten Sandset	29
14	Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer 2004 ·Acta Oncologica ·Erik A. Wist, (unknown), Bjørn Østenstad, Terje Risberg, Yngve Bremnes, (unknown)	50
15	Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer 2004 ·Acta Oncologica ·Erik A. Wist, (unknown), Bjørn Østenstad, Terje Risberg, (unknown)	20
16	Analysis of the humoral immune response to immunoselected phage‐displayed peptides by a microarray‐based method 2004 ·PROTEOMICS ·Lina Cekaite, (unknown), Ola Myklebost, Magne Aldrin, Bjørn Østenstad, Marit Holden, Arnoldo Frigessi, Eivind Hovig, Mouldy Sioud	23
17	C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer 2002 ·European Journal of Cancer ·J Sjöström, Juhani Collan, Kristina von Boguslawski, Kaarle Franssila, Nils‐Olof Bengtsson, Ingvil Mjaaland, Annika Malmström, Bjørn Østenstad, E. Wist, Vahur Valvere, Jonas Bergh, (unknown), E Saksela, Carl Blomqvist	36
18	Identification of immunogenic antigens using a phage-displayed cDNA library from an invasive ductal breast carcinoma tumour 2001 ·International Journal of Oncology ·Mona Hansen, Bjørn Østenstad, Mouldy Sioud	27
19	Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian Breast Group 2000 ·European Journal of Cancer ·Liisa Hakamies‐Blomqvist, Minna‐Liisa Luoma, J Sjöström, A Płużańska, Marie Sjödin, Henning T. Mouridsen, Bjørn Østenstad, Ingvil Mjaaland, (unknown), Jonas Bergh, Per Malmström, Carl Blomqvist	38
20	Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area. 1994 ·Gut ·Bjørn Østenstad, T. Lea, Ellen Schlichting, M Harboe	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact